Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Her2-negative Or Low Expression As An Unfavorable Prognostic Factor In Patients With Stage I/ii Uterine Carcinosarcoma.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Her2-negative Or Low Expression As An Unfavorable Prognostic Factor In Patients With Stage I/ii Uterine Carcinosarcoma.

Related Experiment Video

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K

HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma.

Chiharu Mizoguchi1, Tadaaki Nishikawa2, Hiroshi Yoshida3

  • 1Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Journal of Gynecologic Oncology
|July 11, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Human epidermal growth factor receptor 2 (HER2) low expression in uterine carcinosarcoma (UCS) indicates poor survival. HER2 IHC score alone is a prognostic factor for early-stage UCS, suggesting potential for targeted therapies.

Keywords:
CarcinosarcomaERBB2 Protein, HumanImmunohistochemistryIn Situ Hybridization

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.6K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.6K

Related Experiment Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.6K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.6K

Area of Science:

  • Oncology
  • Pathology
  • Molecular Diagnostics

Background:

  • Uterine carcinosarcoma (UCS) is a rare, aggressive endometrial cancer with limited therapeutic options.
  • The prognostic and predictive role of human epidermal growth factor receptor 2 (HER2) in UCS remains incompletely understood.

Purpose of the Study:

  • To evaluate the prognostic significance of HER2 protein expression and gene amplification in UCS.
  • To identify clinicopathologic characteristics associated with HER2-low UCS.

Main Methods:

  • HER2 protein expression was assessed using immunohistochemistry (IHC) in 148 UCS patients.
  • HER2 gene amplification was analyzed via fluorescence in situ hybridization (FISH) in 72 patients.
  • HER2 IHC scoring followed ASCO/CAP guidelines for gastric cancer.
Prognosis

Main Results:

  • HER2 expression was categorized as negative (41 patients), low (1+, 57 patients), or high (2+/3+, 50 patients).
  • HER2-negative and low expression correlated with poorer overall survival in early-stage (I/II) UCS compared to high expression.
  • HER2 IHC score alone, but not combined with FISH, served as a prognostic factor in stage I/II UCS.

Conclusions:

  • HER2 IHC score is a significant prognostic factor in early-stage UCS.
  • HER2-low expression in advanced UCS warrants further investigation for targeted therapeutic strategies.
  • Stratification of UCS patients based on HER2 IHC score may facilitate the development of novel adjuvant therapies.